Ablynx has entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate Nanobodies against a multiple sclerosis (MS) target that relates to Genzyme’s early-stage MS research programs involving neuroprotection and CNS repair.   Existing drugs do not directly treat the neurodegeneration in MS. Genzyme’s research efforts aim to target the underlying causes of MS disease progression and develop treatments to protect neurons and promote repair.   Genzyme...